Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17397682 | 0.73 | KDM4E (0.37) | KDM4EGAAMEN1ALDH1A1MAPT | |
| SCHEMBL8790746 | 0.69 | ADORA2A (0.38) | KDM4EGAAMAPT | |
| SCHEMBL23635064 | 0.65 | TXNRD1 (0.40) | ALDH1A1 | |
| SCHEMBL10158539 | 0.65 | MAPT (0.42) | KDM4EGAAMEN1ALDH1A1POLB | |
| SCHEMBL5537181 | 0.64 | MMP12 (0.35) | KDM4EGAAMAPT | |
| SCHEMBL1429290 | 0.63 | KDM4E (0.44) | APPKDM4EGAAMEN1ALDH1A1 | |
| SCHEMBL30019143 | 0.63 | CYP19A1 (0.53) | KDM4EGAAALDH1A1MAPTHTT | |
| SCHEMBL30954241 | 0.63 | PSMB5 (0.33) | — | |
| SCHEMBL21236396 | 0.63 | USP8 (0.36) | KDM4EGAAMEN1KMT2A | |
| SCHEMBL5537188 | 0.63 | KDM4E (0.41) | KDM4EGAAMEN1ALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2881397-B1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | UNIV KYOTO (JP) | 2020-09-02 | — | — | EP | disclosed |
| EP-2881397-B1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | UNIV KYOTO (JP) | 2020-09-02 | — | — | EP | disclosed |
| CN-106986865-B | Compound and pharmaceutical composition for mental and neurological diseases or malignant tumors | 国立大学法人京都大学 | 2020-02-28 | — | — | CN | disclosed |
| US-10017524-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2018-07-10 | — | — | US | disclosed |
| US-10017524-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2018-07-10 | — | — | US | disclosed |
| US-10017524-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2018-07-10 | — | — | US | disclosed |
| US-20170355715-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2017-12-14 | — | — | US | disclosed |
| US-20170355715-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2017-12-14 | — | — | US | disclosed |
| US-20170355715-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2017-12-14 | — | — | US | disclosed |
| US-9745323-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | KYOTO UNIVERSITY (JP) | 2017-08-29 | — | — | US | disclosed |
| US-20160303089-A1 | COMPOUND PERTAINING TO NEUROPOIESIS AND DRUG COMPOSITION | KYOTO UNIVERSITY (JP) | 2016-10-20 | — | — | US | disclosed |
| US-20160303089-A1 | COMPOUND PERTAINING TO NEUROPOIESIS AND DRUG COMPOSITION | KYOTO UNIVERSITY (JP) | 2016-10-20 | — | — | US | disclosed |
| US-20160303089-A1 | COMPOUND PERTAINING TO NEUROPOIESIS AND DRUG COMPOSITION | KYOTO UNIVERSITY (JP) | 2016-10-20 | — | — | US | disclosed |
| US-20150225421-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225421-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225421-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | KYOTO UNIVERSITY (JP) | 2015-08-13 | — | — | US | disclosed |
| WO-2015083750-A1 | COMPOUND PERTAINING TO NEUROPOIESIS AND DRUG COMPOSITION | 国立大学法人京都大学 | 2015-06-11 | — | — | WO | disclosed |
| EP-2881397-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | Kyoto University (JP) | 2015-06-10 | — | — | EP | disclosed |
| EP-2881397-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | Kyoto University (JP) | 2015-06-10 | — | — | EP | disclosed |
| CN-104520303-A | Compound and pharmaceutical composition for mental and neurological diseases or malignant tumors | NAT UNIV CORP KYOTO UNIV | 2015-04-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225421-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | VHL, TP53, COMT | APP 17/4885KDM4E 2440/4885GAA 208/4885 |
| US-20170355715-A1 | COMPOUND AND PHARMACEUTICAL COMPOSITION FOR NEUROPSYCHOLOGICAL DISORDER OR MALIGNANT TUMOR | VHL, TP53, COMT | APP 17/4885KDM4E 2440/4885GAA 208/4885 |
| US-20160303089-A1 | COMPOUND PERTAINING TO NEUROPOIESIS AND DRUG COMPOSITION | BDNF, DCX, NTRK2 | APP 463/4885KDM4E 1643/4885GAA 1355/4885 |
| US-10017524-B2 | Compound and pharmaceutical composition for neuropsychological disorder or malignant tumor | VHL, TP53, COMT | APP 17/4885KDM4E 2440/4885GAA 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.